Oncology is increasingly incorporating precision medicine approaches that consider the genetic, molecular, and biological characteristics of individual cancers. These approaches may help healthcare professionals better understand disease characteristics and support treatment planning. Advances in cancer research have enabled the development and use of various precision medicine tools for the diagnosis, treatment selection, and monitoring of patients with cancer.

The oncology treatment landscape has evolved with the increasing integration of precision medicine approaches. Advances in genomic sequencing, molecular diagnostics, targeted therapies, and data-driven technologies have expanded the tools available to healthcare professionals for evaluating and managing various solid tumors and hematologic malignancies. These developments have contributed to a more detailed understanding of cancer biology and have supported the use of treatment strategies informed by individual disease characteristics. As precision medicine continues to develop, a range of diagnostic and therapeutic approaches are being explored across multiple cancer types, including some rare cancers.

Understanding Precision Medicine in Oncology

Precision medicine is a form of treatment that is designed for individual patients based on the unique characteristics of their disease. This approach differs from conventional cancer treatment, where patients with the same type and location of cancer are typically given the same treatment. In reality, the biology of each cancer is different, and precision medicine takes into account a wide array of characteristics that determine the cancer’s behavior, such as genetic mutations, protein expression, and cancer cell signaling pathways. Most importantly, precision medicine enables patients to be treated with therapies that target specific characteristics of their cancer, in addition to avoiding treatments that are unlikely to provide benefit and are likely to cause significant harm.

Precision medicine is an individualized approach to cancer care that considers the biological characteristics of a patient’s cancer. In addition to traditional diagnostic factors, these insights may help healthcare professionals better understand disease features and inform treatment planning.

The use of precision medicine has become increasingly integrated into the management of several cancer types, including breast, lung, colorectal, pancreatic, and melanoma, as well as hematologic malignancies such as leukemia and lymphoma, even some less common malignancies.

The Role of Genomic Testing

Comprehensive genomic testing is the core of how precision oncology is practiced as part of precision medicine. The amount of data generated from the thousands of genes in a cancer sample has exponentially increased over the last few years. This enables identification of all mutations in a cancer and subsequently enables matching each patient with the most suitable treatment. In order to find out how different targeted therapies such as zanubrutinib vs acalabrutinib work in patients with specific molecular profiles, comparative research is performed within the scope of precision oncology. This information may support treatment decision-making by healthcare professionals.

Modern genomic testing can detect:

• Gene mutations
• Gene fusions
• Chromosomal abnormalities
• Copy number variations
• Biomarker expression
• Hereditary cancer risk factors

A tumor’s genomic profile may provide insights into its molecular characteristics, helping inform treatment planning and the evaluation of potential therapeutic options, including targeted therapies and clinical trials, based on individual disease features.

Targeted Therapies for Cancer Care

Targeted therapies are a component of precision medicine that are designed to act on specific molecular features of certain cancers. These therapies may target proteins or signaling pathways associated with cancer cell growth and are selected based on the biological characteristics of a patient’s disease and clinical assessment.

Some targeted therapies have been evaluated in clinical studies and may have different efficacy and safety profiles compared with other treatment approaches.

Examples of targeted treatment strategies include:

• Tyrosine kinase inhibitors
• Monoclonal antibodies
• Antibody-drug conjugates
• PARP inhibitors
• BRAF inhibitors
• EGFR inhibitors
• ALK inhibitors

Ongoing research into the molecular characteristics of cancer continues to support the development and evaluation of targeted therapies for a range of cancer types.

Precision Medicine in Blood Cancers

Precision medicine approaches are being used in the evaluation and management of various blood cancers, including CLL, CML, AML, multiple myeloma, and certain lymphomas. 

Today’s approach to treating blood cancers focuses on identifying specific genetic abnormalities that in part determine a patient’s prognosis. By using molecular diagnostics, a patient’s individual cancer can be analyzed to identify potential targets for therapies developed to attack specific molecular pathways of cancer cells. Targeted therapies have been evaluated for certain patients as an alternative to chemotherapy.

As more therapies are developed for the treatment of various cancers, it will become increasingly important to perform head-to-head studies comparing specific therapies within particular classes (i.e. zanubrutinib vs acalabrutinib for B-cell malignancies). These studies will provide more information as to which targeted therapies are best for the treatment of patients with specific types and stages of cancer. Furthermore, a more comprehensive understanding of the effects of these treatments with regards to safety, tolerability and long-term outcomes will also be needed.

Biomarkers Are Guiding Treatment Decisions

Frequently evaluated biomarkers include:

• PD-L1 expression
• HER2 status
• BRCA mutations
• KRAS mutations
• EGFR mutations
• ALK rearrangements
• MSI status

These biomarkers can be used to develop individualized treatment plans for patients and lead to successful therapy.

Artificial Intelligence and Precision Oncology

Innovations in cancer research, including the use of Artificial Intelligence (AI), are revolutionizing the treatment of this disease. By processing and analyzing large volumes of genomic data, medical images, pathology reports, and other information about a patient’s cancer and treatment, the most effective treatments can be identified and a number of factors that might suggest success or failure of particular treatments can be predicted.

AI-supported technologies are helping researchers:

• Interpret complex genomic data
• Identify potential treatment targets
• Predict treatment response
• Improve diagnostic accuracy
• Support clinical decision-making
• Accelerate drug discovery

Although clinical judgment by the doctor is essential, in the future AI will play a larger role in cancer treatment.

Liquid Biopsies Are Expanding Diagnostic Possibilities

Liquid biopsies involve the analysis of circulating tumor DNA and other blood-based biomarkers to provide molecular information about a patient’s cancer. This approach is being evaluated for applications such as disease monitoring, assessment of treatment response, and detection of molecular changes over time.

Potential applications include:

• Early cancer detection
• Monitoring treatment response
• Detecting minimal residual disease
• Identifying resistance mutations
• Tracking disease progression
• Guiding treatment adjustments

New advances in liquid biopsy technology are becoming increasingly important in cancer diagnosis and monitoring and will likely become standard in cancer precision treatment in the near future.

Clinical Trials Continue to Drive Innovation

Thousands of clinical studies currently are under way to evaluate new targeted cancer therapies, cancer immunotherapies, cancer combination therapies and cancer personalized treatment approaches.

Current areas of investigation include:

• Personalized immunotherapy
• Next-generation targeted therapies
• Gene editing technologies
• Cancer vaccines
• Cellular therapies
• Combination precision treatments
• Adaptive clinical trial designs

These studies will further improve existing treatment approaches and also provide patients all over the world with more therapeutic options.

Challenges Facing Precision Medicine

Although significant progress in precision medicine has been made in cancer therapy, there are still many challenges that need to be overcome before this approach can be fully introduced into healthcare systems worldwide.

Common challenges include:

• Limited access to genomic testing
• High treatment costs
• Availability of specialized laboratories
• Data interpretation complexity
• Limited access to clinical trials
• Healthcare infrastructure differences
• Regulatory and reimbursement issues

Addressing these challenges will need to involve all stakeholders including researchers, health care providers, governments, regulatory authorities and pharmaceutical companies to work together.

The Future of Global Oncology

The future of oncology will be precision cancer medicine or targeted individualized cancer therapy. Such new era of cancer treatment will enable doctors to individualize the best treatment plan for each patient with new developments in the field of cancer biology. There will be improved genomic sequencing technologies, artificial intelligence, more molecular diagnostic tests, and more targeted cancer therapies to develop.

International collaboration, more clinical studies and greater access to advanced diagnostics will fuel the advance of precision cancer medicine and may improve diagnosis and treatment selection for patients all over the world. As new biomarkers are identified and more targeted agents come to market, ongoing research continues to evaluate effects on clinical outcomes and quality of life.

Key Takeaways

Precision medicine has become an important component of modern oncology, incorporating genomic, molecular, and clinical information into cancer care. Advances in diagnostic technologies, biomarker identification, targeted therapies, and data-driven tools may support treatment decision-making and contribute to a more personalized approach to patient management. Ongoing studies continue to evaluate the potential applications of these approaches across different cancer types. Continued advancement of personalized cancer treatment is set to lead to improvements in survival rates, patient quality of life and cure rates for a variety of cancers, making precision medicine a key driver of future global cancer treatment.